Access to investigational therapies is already permitted through the FDA expanded access program. FDA currently approves 99.7% of all expanded access requests submitted by physicians and companies for patients with immediately life-threatening illnesses who cannot participate in clinical trials. Removing FDA from the process of obtaining investigational drugs, as Right to Try proposes, increases the risk of patient harm and creates confusion.
For more information, check out our one-pager on the legislation here!